Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin for Treating Erythema/Flushing in Rosacea
NCT06776445Phase 1Completed
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of gabapentin in rosacea (3 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Clinician Erythema Assessment at 12 weeks. Started Jan 2024; status: completed.
02
Drugs
gabapentin
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT06776445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06776445.